Istiratumab
Catalog No.: PC0126
Size: 1 mg, 5 mg,10 mg
Description
Istiratumab (M-6495) is a bispecific monoclonal antibody against IGF-1R and ErbB3 that induces degradation of IGF-1R and ErbB3 receptors through the proteasomal pathway and can be used in cancer research.
| CAS No. |
1509928-04-4 |
| Shipping |
Room temperature in continental US; may vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| In Vitro |
Istiratumab (500 nM, 24 h) inhibits AKT activation in response to IGF-1 and HRG costimulation in human pancreatic cancer cell lines.
Istiratumab (500 nM, 24 h) inhibits IGF-1- and HRG-induced AKT phosphorylation in pancreatic cancer cells that harbor activating KRAS mutations.
Istiratumab (500 nM, 24 h) induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway.
Istiratumab (1 μM, 60 min) block activation of the PI3K and MAPK signaling cascades in ovarian cancer cell lines. |
All of our services are intended for preclinical research
use only and cannot be used to diagnose, treat or manage patients.
